CD274 and neoplasm: Tumor PD-L1 expression and the tumor immune microenvironment were previously reported to be affected by cytotoxic agents, which could explain the synergistic effects of the combination of anti-PD-1/L1 inhibitors and chemotherapy (41, 42).